Prognostic Significance and Functional Role of CEP57 in Prostate Cancer  by Mang, Josef et al.
www.transonc.com
Trans la t iona l Onco logy Volume 8 Number 6 December 2015 pp. 487–496 487
Address al
ogy, Depa
Medical F
Germany.
E-mail: ste
1This worPrognostic Significance and
Functional Role of CEP57 in
Prostate Cancer1l correspondence to: Stefan Duensing, Section of Molecular Urooncol-
rtment of Urology, University of Heidelberg School of Medicine,
aculty Heidelberg, Im Neuenheimer Feld 517, D-69120 Heidelberg,
fan.duensing@med.uni-heidelberg.de
k was supported by the Medical Faculty Heidelberg.Josef Mang*, Nina Korzeniewski*, Dimo Dietrich†,
Verena Sailer†, Yanis Tolstov*, Sam Searcy*,
Jost von Hardenberg‡, Sven Perner§,
Glen Kristiansen†, Alexander Marx¶, Wilfried Roth#,
Esther Herpel#,**, Carsten Grüllich††,
Valentin Popeneciu‡‡, Sascha Pahernik‡‡,
Boris Hadaschik‡‡, Markus Hohenfellner‡‡ and
Stefan Duensing*,‡‡
*Molecular Urooncology, Department of Urology, Medical
Faculty Heidelberg, University of Heidelberg, Im Neuenheimer
Feld 517, D-69120 Heidelberg, Germany; †Institute of
Pathology, University of Bonn School of Medicine,
Sigmund-Freud-Strasse 25, D-53127 Bonn, Germany;
‡Department of Urology, Medical Faculty Mannheim,
University of Heidelberg, Theodor-Kutzer-Ufer 1-3, D-68167
Mannheim, Germany; §Pathology Network of the
University Hospital of Lübeck and Leibniz Research Center
Borstel, Ratzeburger Allee 160, D-23538 Lübeck,
Germany; ¶Institute of Pathology, Medical Faculty
Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer
1-3, D-68167 Mannheim, Germany; #Institute of
Pathology, University of Heidelberg School of Medicine,
Im Neuenheimer Feld 224, D-69120 Heidelberg, Germany;
**Tissue Bank of the National Center for Tumor Diseases
(NCT), Im Neuenheimer Feld 220/221, D-69120 Heidelberg,
Germany; ††National Center for Tumor Diseases (NCT),
Department of Medical Oncology, Im Neuenheimer Feld
460, D-69120 Heidelberg, Germany; ‡‡Department of
Urology, University of Heidelberg School of Medicine, Im
Neuenheimer Feld 110, D-69120 Heidelberg, GermanyAbstract
We have recently shown that centrosomal protein 57 (CEP57) is overexpressed in a subset of human prostate
cancers. CEP57 is involved in intracellular transport processes, and its overexpression causes mitotic defects as
well as abnormal microtubule nucleation and bundling. In the present study, we further characterized the
prognostic and functional role of CEP57 in prostate cancer. Unexpectedly, we found that high CEP57 expression is
an independent prognostic factor for a more favorable biochemical recurrence-free survival in two large patient
cohorts. To reconcile this finding with the ability of CEP57 to cause cell division errors and thus potentially
promote malignant progression, we hypothesized that alterations of microtubule-associated transport processes,
in particular nuclear translocation of the androgen receptor (AR), may play a role in our finding. However, CEP57
overexpression and microtubule bundling had, surprisingly, no effect on the nuclear translocation of the AR.
Instead, we found a significant increase of cells with disarranged microtubules and a cellular morphologyReceived 30 September 2015; Accepted 10 November 2015
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488 Role of CEP57 in Prostate Cancer Mang et al. Translational Oncology Vol. 8, No. 6, 2015suggestive of a cytokinesis defect. Because mitotic dysfunction leads to a reduced daughter cell formation, it can
explain the survival benefit of patients with increased CEP57 expression. In contrast, we show that a reduced
expression of CEP57 is associated with malignant growth and metastasis. Taken together, our findings underscore
that high CEP57 expression is associated with mitotic impairment and less aggressive tumor behavior. Because
the CEP57-induced microtubule stabilization had no detectable effect on AR nuclear translocation, our results
furthermore suggest that microtubule-targeting therapeutics used in advanced prostate cancer such as docetaxel
may have modes of action that are at least in part independent of AR transport inhibition.
Translational Oncology (2015) 8, 487–496Introduction
Prostate cancer is the most commonly diagnosed noncutaneous
malignancy in men in developed countries. Prostate cancer is the
second leading cause of male cancer-related death in the United States
and the third leading cause in Europe [1].
Although prostate-specific antigen (PSA) screening has resulted
in a decrease of prostate cancer–related mortality [2], this major
achievement comes at the cost of overtreatment of indolent tumors.
It is hence of paramount importance to identify markers that can
help to further define subgroups of patients for a risk-adapted,
individualized treatment.
Prostate cancer is characterized by chromosomal instability
including aneuploidy [3]. Aneuploidy is frequently caused by cell
division errors [4] due to centrosome amplification, and such
aberrations are likewise frequently detected in prostate cancer [5].
We have recently shown that the centrosomal protein 57 kDa
(CEP57) is overexpressed in a subset of prostate cancers [6]. CEP57
has an N-terminal centrosome localization and multimerization
domain and a C-terminal microtubule-binding and stabilization
domain [7]. CEP57 was first described as a mediator of
microtubule-dependent internalization and nuclear trafficking of
the 18-kDa isoform of fibroblast growth factor type 2 (FGF-2, basic
FGF) [8]. CEP57 has been shown to be critically involved in
FGF-2-induced centrosome overduplication, and ectopic expression
of CEP57 alone has been demonstrated to induce centriole
overduplication and mitotic instability [6]. CEP57 overexpression
also leads to a stabilization of microtubules and a striking formation
of microtubule bundles that have been referred to as "basket"
structures [7].
Growth and differentiation of the prostate gland during
development are dependent on androgens, and prostate cancers are
also initially androgen dependent [9]. Androgen signaling is
mediated through the androgen receptor (AR), a ligand-activated
transcription factor. Targeting the androgen-AR axis by androgen
deprivation therapy (ADT) therefore represents the first-line therapy
for advanced prostate cancer [10]. Although most patients with
advanced prostate cancer initially respond to ADT, they ultimately
develop resistance leading to a metastatic castration-resistant stage
(mCRPC) [11]. Despite circulating androgens at castrate level,
castration-resistant prostate cancer cells still critically depend on
androgen signaling, and a number of mechanisms have been
identified that maintain these signaling cues [12–14]. Patients
with mCRPC are frequently treated with docetaxel, a microtubule-
stabilizing drug that is believed to function through its antimitoticeffects and, in a typically slowly growing tumor such as prostate
cancer, other mechanisms such as inhibition of the microtubule-
dependent nuclear translocation of the AR [15].
In the present study, we show that high CEP57 expression
characterizes a subset of prostate cancer patients with a more favorable
prognosis. We attribute this finding to a growth-suppressive effect of
CEP57 overexpression that involves a failure to produce daughter
cells due to impaired cell division. In contrast to our initial
hypothesis, a blockade of the nuclear translocation of the AR caused
by microtubule bundling appears not to play a role in the more
favorable prognosis of patients with CEP57 overexpression. These
findings have a number of translational implications for the prognosis
and treatment of prostate cancer.
Material and Methods
Cell Culture, Transfections, and Drug Treatment
Human prostate cancer cell lines LNCaP and PC-3 and mouse
NIH3T3 cells were obtained from CLS Cell Line Service
(Eppelheim, Germany) and maintained according to the distribu-
tor's recommendations. For transient DNA transfection, the
following plasmids were used: murine (m)CEP57-myc-flag (kindly
provided by Ko Momotani University of Virginia, Charlottesville,
VA) [7], pCMV6-myc-flag empty vector (Origene, Rockville, MD),
centrin-GFP (kindly provided by Michel Bornens, Institut Curie,
Paris, France) [16], mitochondrial DsRed (Clontech, Mountain
View, CA), and AR-C1-pEGFP and C1-pEGFP empty vector
(Addgene, Cambridge, MA). LNCaP and PC-3 cells were transfected
using the Neon Transfection System (Life Technologies, Carlsbad,
CA) according to instructions provided by the manufacturer. Briefly,
70% to 90% confluent cells were harvested and then washed twice
with PBS. LNCaP cells, mixed with plasmid DNA, in a 100-μl Neon
tip were electroporated at 1250 V, 2 × 20–millisecond pulse length.
PC-3 cells, mixed with plasmid DNA, in a 100-μl Neon tip were
electroporated at 1250 V, 30-millisecond pulse length. NIH3T3
cells were transfected using lipofection (Fugene; Promega, Madison,
WI). To induce AR nuclear translocation, cells were treated with
5 nMR1881 or DMSO as control for 2 hours and analyzed thereafter
by fluorescence microscopy.
Antibodies
The following antibodies were used: mouse anti-CEP57 (Abcam,
Cambridge, UK), rabbit anti-AR, rabbit anti-FGF2, mouse anti-α-
tubulin (all from Santa Cruz, Santa Cruz, CA), rabbit anti-myc-tag (Cell
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anti-Ki67 (Dako, Glostrup, Denmark), and rabbit anti–fibroblast growth
factor receptor 1 (FGFR1) (Sigma-Aldrich, St. Louis, MO).
Immunofluorescence Microscopy
Cells were grown on coverslips, fixed in 4% paraformaldehyde/PBS
for 10 minutes at room temperature, washed with PBS, permeabilized
with 1% Triton-X100/PBS for 10 minutes at room temperature, and
washed in PBS. Fixed cells were then incubated with primary antibody
diluted in PBS at 4°C overnight. Dilutions for primary antibodies
were as follows: anti-myc-tag (1:200) and anti-α-tubulin (1:200). The
following day, cells were incubated for 2 hours at room temperature
with secondary antibody Alexa Fluor 488 or Alexa Fluor 555 (Life
Technologies) diluted 1:1000 in PBS and then again washed with PBS.
Finally, cells were mounted with DAPI-containing mounting medium
(Vectashield; Vector Laboratories, Burlingame, CA). Cells were
analyzed using a Leica DM5000B fluorescence/brightfield microscope.
Immunohistochemistry
Patient-derived tumor specimens were collected under approval by the
Ethics Committee of the Medical Faculty of the University of Bonn
(071/14), the Medical Faculty Heidelberg of the University of
Heidelberg (206/2005, 207/205, S-085/2012), and theMedical Faculty
Mannheim of the University of Heidelberg (2012-229N-MA). Tissue
samples from the tissue bank of the National Center for Tumor Diseases
Heidelberg were provided in accordance with the regulations of the tissue
bank and the approval of the Ethics Committee of the University of
Heidelberg. Two tissue microarrays (TMAs) were used in this study:
TMA I was obtained commercially (TriStar Technology Group,
Washington, DC), and TMA II was constructed by the Institute of
Pathology of the University of Bonn. Age, PSA at diagnosis, and TNM
status were comparable between the two TMAs. However, TMA I
contained only 1.2% of tumors with a Gleason score N7 in comparison
to 21.2% in TMA II. Information about adjuvant treatment was not
available for TMA I. A total of 45 of 212 patients of the TMA II cohort
received adjuvant radiotherapy. There was no statistical difference
between patients with adjuvant radiotherapy and without radiotherapy
with respect to CEP57 staining (P = .18; chi-square). Briefly,
paraffin-embedded tissue was incubated overnight at 37°C. Next day,
the slides were deparaffinized by incubating in xylene for 12 minutes
followed by a graded ethanol series (100%, 90%, and 70% for 4minutes
each). Antigen retrieval was performed using a steamer for 30 minutes
and target retrieval solution (Dako) diluted 1:10 in dH2O. Primary
antibodies were incubated at 4°C overnight diluted in PBS using the
following dilutions: anti-CEP57 (1:100), anti-p63 (1:75), anti-AR
(1:100), anti-FGF-2 (1:100), anti-FGFR1 (1:100), and anti-Ki-67
(1:100). Immunodetection was performed using the HistostainPlus kit
(Life Technologies) according to manufacturer's recommendations.
3-(4,5 Dimethyldiazol-2-yl)-2,5 Diphenyltetrazolium Bromide
(MTT) Assay
Cells were grown in 60-mm tissue culture plates, and the Vybrant
MTTCell Proliferation Assay kit (Life Technologies) was used according
to manufacturer's instructions. Briefly, 12 mMMTT stock solution was
prepared using 1 ml of PBS for each vial of MTT. MTT stock solution
then was diluted 1:10 in cell culture media, and cells were incubated for
4 hours at 37°C. After 4 hours, 10 mMHCl containing 0.1 g/ml of SDS
was added to the MTT-containing media to a final dilution of 1:1. Cells
were then incubated for 18 hours at 37°C beforemeasuring absorbance at
570 nm with the Glomax Multi luminometer (Promega, Madison, WI).Statistical Methods
Associations between clinicopathological variables and CEP57
protein expression were analyzed using the Kendall τ rank correlation,
χ2 test, or Fisher exact probability test. Student’s two-tailed t test for
independent samples was performedwherever appropriate. Biochemical
recurrence (BCR)-free survival was calculated using the Kaplan-Meier
method, and survival time differences were compared using the log-rank
test. CEP57 expression was also examined within univariate and
multivariate Cox proportional hazards regression models. P values refer
to the Wald test. P values b .05 were considered to be statistically
significant. All analyses were carried out using the SPSS software
package (IBM, Armonk, NY).
Results
CEP57 Overexpression and Biochemical Recurrence-Free Survival
of Prostate Cancer Patients
We have previously reported that CEP57 is overexpressed in a subset
of prostate cancers, whereas normal tissue consistently shows no or a
weak to moderate expression [6]. However, a correlation to patient
survival was not possible in our earlier study because of a lack of clinical
follow-up information. Here, we addressed this question by first staining
a commercially available TMA containing 500 prostate cancer samples
with survival data for CEP57 by immunohistochemistry. A total of 341
out of 500 cores were evaluable for scoring of CEP57 expression (J.M.
and S.D.). We found that 186 of 341 (55%) samples showed a high
CEP57 expression, whereas 155 of 341 (45%) showed a low (negative or
weak to moderate) expression of CEP57 (Suppl. Table 1; Figure 1, A
and B). Kaplan-Meier analysis revealed a trend toward a more favorable
BCR-free survival for patients with high CEP57 expression compared
with patients with low CEP57 expression over a 60-month follow-up
period (log-rank, P b .05; Figure 1B).
We next sought to confirm our findings using a second, independent
TMA constructed at the University of Bonn Medical School (V.S.,
D.D., G.K.). A total of 212 patient specimens were scored for CEP57
expression after immunohistochemical staining. Absence of CEP57 was
detected in 1 of 212 specimens (0.3%), 72 of 212 samples showed a
weak CEP57 expression (24%), moderate expression was found in 104
of 212 samples (34.7%), whereas 35 of 212 specimens showed a high
CEP57 expression (11.7%; Suppl. Table 2). Kaplan-Meier analysis of
this second patient cohort confirmed a significantly better BCR-free
survival for patients with tumors showing high CEP57 expressing
compared with patients with lower expression (log-rank, P = .006;
Figure 1C). We next performed a univariate and multivariate Cox
analysis (Table 1). The N stage was not prognostic because of the small
number of N1 patients (14/212). Pathological T stage and Gleason
score were both significant prognosticators in the univariate analysis,
whereas the T stage lost its significance in the multivariate analysis
because of its association with the Gleason score. Importantly, however,
we found that CEP57 was an independent prognostic factor for
BCR-free patient survival (Table 1).
CEP57 Overexpression Impairs Cell Viability In Vitro
Independent of AR Nuclear Transport
To determine possible biological mechanisms involved in the more
favorable BCR-free patient survival associated with high CEP57
expression, a number of in vitro experiments were performed. We
first overexpressed CEP57 in prostate cancer cells and analyzed CEP57
and α-tubulin staining by co-immunofluorescence microscopic analysis
to test its functionality. We readily detected "basket" structures [7]
Table 1. Univariate and Multivariate Cox Proportional Hazard Model Analyses on BCR-Free
Survival for CEP57 Protein Expression, Gleason, pT, Preoperative PSA Level, Surgical Margin, and
Nodal Status
Univariate Cox Analysis Multivariate Cox Analysis
Hazard Ratio [95%CI] PValue Hazard Ratio [95%CI] PValue
Pathological stage (pT2 reference)
pT3 and pT4 2.15 [1.18-3.92] .012 1.11 [0.56-2.19] .76
Gleason sum (7 reference)
b7 0.33 [0.14-0.81] 0.28 [0.11-0.72]
N7 3.854 [1.89-7.85] b .001 3.22 [1.51-6.86] b .001
Nodal status (N0 reference)
N1 1.16 [0.45-3.54] .66 0.50 [0.14-1.77] .28
Surgical margin (R0 reference)
R1 1.89 [1.03-3.47] .039 2.03 [1.03-3.99] .041
Preoperative PSA 1.01 [0.99-1.02] .47 1.00 [0.98-1.02] .96
CEP57 0.63 [0.40-0.99] .045 0.55 [0.32-0.92] .022
Gleason score was analyzed as categorized (b7, 7, and N7) variable. Preoperative PSA level was
analyzed as continuous variable.
Figure 1. High CEP57 expression is associated with more favorable
BCR-free survival in two cohorts of prostate cancer patients. (A)
Examples of immunohistochemical staining for CEP57 in two
prostate cancer specimens with low or high protein expression,
respectively. Scale bar = 250 μm. (B, C) Kaplan-Meier curves of
BCR-free survival using two TMAs either obtained commercially
(TMA I) or collected at the University of Bonn School of Medicine
(TMA II). The log-rank test was used to calculate P values.
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CEP57, whereas such structures were absent in control-transfected cells
(Figure 2A). To further verify that CEP57 was functional, we also
showed that transient overexpression induced centriole overduplication
as previously reported (Figure 2, B and C) [6].
We next investigated the effect of CEP57 overexpression on cell
viability. LNCaP cells were transiently transfected with either a control
plasmid or a CEP57 expression plasmid, and cell viability was measured
after 48 hours using the MTT assay (Figure 3). A moderate butstatistically significant reduction of cell viability was found in
CEP57-overexpressing cells compared with control-transfected cells
(88.8% normalized to controls; P b .001). This decrease of viability was
in the range of cells treated with 50 nM docetaxel (76.5%; P b .0001).
A combination of CEP57 overexpression and docetaxel treatment led to
a further reduction of cell viability (67.8%; P b .0001). These results
underscore that high CEP57 expression impairs the viability of prostate
cancer cells to a similar extent than docetaxel.
CEP57 has previously been implicated in a number of potentially
oncogenic mechanisms related to aberrant microtubule and/or
centrosomal functions [6,8,17]. However, because we detected a more
favorable effect on patient survival and reduced viability of prostate
cancer cells in vitro upon overexpression, we hypothesized that other
functions of CEP57 may override potentially pro-oncogenic properties.
To this end, we postulated that the microtubule-bundling function of
CEP57 may interfere with nuclear transport of the AR. This process is
essential for prostate cancer cell viability, and interference with AR
trafficking has been implicated in themode of action of anticancer agents
used in prostate cancer including taxanes and enzalutamide [18,19].
To examine this notion, we used an AR transport assay on the
single-cell level using a plasmid that expresses AR tagged with green
fluorescent protein (AR-GFP). We transiently transfected PC-3 cells,
which do not express the AR physiologically, with AR-GFP or GFP
control plasmid, respectively (Figure 4). We then determined AR
nuclear transport following stimulation of cells with the synthetic
androgen R1881 or DMSO as control. Treatment with R1881
resulted in a robust nuclear relocalization of AR-GFP, whereas
DMSO treatment did not induce nuclear translocation (Figure 4).
To examine AR translocation in the presence or absence of CEP57
overexpression, we transfected PC-3 cells with AR-GFP plus CEP57 or
AR-GFP plus empty vector as control, respectively, and stimulated the
cells with R1881 or DMSO (Figure 5). Surprisingly, CEP57
overexpression did not block AR-GFP translocation to the nucleus
despite a clearly detectable induction of microtubule bundles
(Figure 5A). To rule out that this finding was not due to the fact that
PC-3 cells lack AR expression, we repeated this experiment in
hormone-sensitive LNCaP cells that harbor a mutated AR and observed
the same result as in PC-3 cells (Figure 5B). Taken together, these
findings suggest that CEP57-induced microtubule bundling does not
block microtubule-mediated AR translocation to the nucleus.
Figure 2. CEP57 overexpression induces microtubule bundling and promotes centriole overduplication. (A) Co-immunofluorescence
microscopic analysis of CEP57 and α-tubulin to visualize CEP57-induced microtubule bundles (“basket”) in mouse NIH3T3 cells
overexpressing either empty vector (control) or murine (mCEP57). Nuclei stained with DAPI. Scale bar = 10 μm. (B) Immunofluorescence
microscopic analysis of centrioles in LNCaP cells expressing centrin-GFP as a centriole marker and transfected with either empty vector
(control) or mCEP57. A DsRed encoding plasmid was used as transfection control. Nuclei stained with DAPI. Scale bar = 10 μm.
(C) Quantification of overduplicated centrioles (N4 centrioles per cell, N1 daughter at a single maternal centriole) in LNCaP cells transfected
with centrin-GFP together with an empty vector (control) or mCEP57. Statistical analysis was performed using Student's two-tailed t test for
independent samples.
Figure 3. Overexpression of CEP57 is growth suppressive. MTT
assay measuring viability of LNCaP cells either 48 hours after
transfection with empty vector (control) or mCEP57 alone or with
docetaxel at a 50-nM concentration. *P b .001, **P b .0001
(Student's two-tailed t test for independent samples).
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In Vivo
We next investigated whether high CEP57 expression interferes
with AR transport in vivo in primary prostate cancer specimens.
Directly adjacent tissue sections from 18 prostate cancers were stained
for CEP57 or AR by immunohistochemistry (Figure 6A). Of the
samples stained, 6 (33.3%) showed a high CEP57 expression,
whereas 12 showed a low CEP57 expression (66.7%, Figure 6B).
Staining for AR was positive in all tumors, with 14 showing strictly
nuclear AR expression (77.8%) and 4 presenting with both nuclear
and cytoplasmic AR staining (22.2%; P N .05).
CEP57 Is Frequently Overexpressed in Prostate Basal Cells
While examining CEP57 expression in these samples, we discovered
that CEP57 was highly overexpressed in areas of prostate basal cell
hyperplasia (Figure 7). To confirm that CEP57-overexpressing cells were
indeed basal cells, we co-stained prostate samples with CEP57 and the
basal cell marker p63, which is typically not expressed in other prostate
cell types including luminal and tumor cells [20]. To further characterize
basal cells with CEP57 overexpression, we also stained for FGF-2 and
FGFR1 because CEP57 plays an important role in FGF-2 signaling
Figure 4. AR transport assay. Fluorescence microscopic analysis of
PC-3 cells following transfection with either a GFP-expressing empty
vector (control) or AR-GFP. Twenty-four hours after transfection, cells
were treated with either 5 nMR1881 or DMSO as a control (2 hours)
to induce AR nuclear translocation. Note the virtually complete
nuclear translocation of AR-GFP after R1881 stimulation. Nuclei
stained with DAPI. Scale bar = 10 μm.
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proliferation. Nine of 18 (47.4%) specimens examined exhibited at least
one noncancerous area where CEP57 overexpression was found
associated with basal cell hyperplasia. CEP57 was coexpressed with
p63 in all of these samples, confirming that the cells overexpressing
CEP57 are indeed basal cells (Figure 7).Of the nine basal cell hyperplasia
regions with CEP57 overexpression, all exhibited strong staining for
FGFR1, although only three of nine were positive for FGF-2 (Figure 7).
When CEP57-positive basal cells were co-stained with the cellular
proliferation marker Ki-67, we did not see a significant coincidence of
the two proteins, underscoring that CEP57-overexpressing basal cells are
largely non-proliferative.
CEP57 Expression Is Lost in Prostate Cancer Metastases
We next examined the expression of CEP57 in tissue specimens
obtained from patients with mCRPC (Figure 8). Primary (n = 11)
and metastatic (n = 5) prostate tumor specimens were collected from
patients undergoing either palliative transurethral resection of the
prostate or resection of a metastatic lesion (lymph node, n = 2; bone,
n = 2, skin, n = 1). Of 11 samples from primary tumors, 7 (63.6%)
showed CEP57 overexpression, whereas 4 samples (36.4%) showed
low CEP57 expression (Figure 8A). Remarkably, all five (100%) of
the metastatic lesions analyzed showed a loss of CEP57 protein
expression (P b .05; Figure 8B).
Taken together, our results suggest that a high CEP57 expression
has a negative impact of prostate cancer cell growth independent of
AR nuclear trafficking and, furthermore, that CEP57 is frequently
lost during malignant progression to a metastatic stage.CEP57 Overexpression Impairs Cell Division
Having shown that overexpression of CEP57 does not block
nuclear translocation of the AR, we performed a detailed microscopic
analysis of CEP57-transfected cells to explain its negative effects
on malignant progression without a strong reduction of tumor
cell viability (Figure 3). CEP57-transfected cells were stained for
α-tubulin to visualize microtubules.
We noticed an increase of cells with a disarranged microtubule
network and abnormal nuclear morphology in comparison to controls
(Figure 9A). These cells frequently contained two nuclei or sometimes
three nuclei and showed a cytoplasmic indentation approximately in the
midzone. A statistically significant three-fold increase of these cells was
detected from 9.8% in controls to 29.6% in CEP57-overexpressing
cells (P b .05).
Such a morphology has previously been described after cytokinesis
failure, and we conclude that CEP57 induces mitotic dysfunction in a
subset of cells that precludes the proper formation of daughter cells.
Such effect could lead to a suppression of tumor cell proliferation,
whereas the viability of cells, at least initially, is not strongly affected.
Discussion
Microtubule-dependent processes play a crucial role in normal and
malignant cellular behavior [22]. CEP57 is a multifunctional protein
that has been implicated in a number of microtubule-associated
processes including microtubule nucleation and their anchoring at the
centrosome as well as bundling of microtubules [7]. It has originally
been identified as a crucial factor for the translocation of the 18-kDa
isoform of FGF-2 (bFGF) into the nucleus [8,21]. CEP57 localizes to
the centrosome and has furthermore been implicated in stable
microtubule attachment at the centrosome and the kinetochore [17].
Recent results have shown that CEP57 forms a complex with the
centrosomal proteins CEP63 and CEP152 [23] and that CEP57 can
stimulate centrosome overduplication and mitotic defects through the
aberrant stabilization of daughter centrioles [6]. We found that
CEP57 is overexpressed in a subset of prostate cancers, a tumor entity
in which FGF-2 signaling [24] and microtubule-dependent transport
processes play pivotal roles in malignant progression.
In the present report, we show that, contrary to our expectations,
high CEP57 expression is not associated with poor patient survival but
instead is associated with a moderate but significant BCR-free survival
advantage in a total of 525 prostate cancer patients analyzed in 2
independent cohorts. In line with this notion, we found a negative
impact of CEP57 overexpression on prostate cancer cell viability and
proper mitosis. However, a link between high CEP57 expression and
nuclear transport of the AR due to aberrantmicrotubule bundling could
not be corroborated. Instead, we found that AR transport remains
normal in cells in which microtubule dynamics are highly altered
by CEP57 overexpression. Furthermore, we discovered that CEP57
expression is frequently lost in prostate cancer metastases. Hence, our
results suggest that negative growth-regulatory functions of CEP57
override its potentially oncogenic activities in prostate cancer, thus
creating selection pressure for its loss.
It is important to mention in this context that CEP57 is not only a
centrosomal protein but also a component of the central spindle and the
midbody [25]. Depletion of CEP57 has previously been reported to
negatively impact on cytokinesis through disruption of these structures,
leading to an increase of binucleated cells [25]. Results shown here
indicate that overexpression of CEP57 likewise affects proper cell
division. Whether and how CEP57 overexpression causes mitotic
Figure 5. CEP57-induced microtubule bundling does not prevent AR nuclear translocation. (A, B) Fluorescence microscopic analysis of
PC-3 (A) or LNCaP (B) cells following transfection with AR-GFP together with either empty vector (control) or mCEP57. Twenty-four hours
after transfection, cells were treated with 5 nM R1881 or DMSO as a control for 2 hours to induce AR nuclear translocation. Note that
microtubule bundling induced by CEP57, which decorates the "baskets," does not prevent nuclear translocation of AR-GFP. Nuclei stained
with DAPI. Scale bar represents 10 μm. Bar graphs show mean and standard error of two independent experiments. P values were
calculated using Student’s two-tailed t test for independent samples.
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midbody remain to be determined. CEP57 has also been shown to be
essential for spindle pole integrity [26], and disruption of this function
due to its overexpression may likewise negatively affect daughter cell
formation. In general, microtubules have been implicated in the
regulation of contractility [27], and CEP57may hence affect contractile
ring formation during mitosis as another potential mechanism leading
to mitotic impairment.CEP57 overexpression has been found to lead to centrosome
aberrations, which can promote chromosomal instability andmalignant
progression [6]. However, centrosome aberrations may not necessarily
provide a growth advantage. In fact, it has previously been shown that
centrosome amplification can hinder cell proliferation [28]. Hence,
reduced proliferation and a decreased ability to generate viable daughter
cells may stem from both centrosome amplification and other
disturbances of microtubule homeostasis.
Figure 6. AR localization is not dependent on CEP57 overexpression in vivo. (A) Immunohistochemical analysis of prostate cancer
specimens for CEP57 and AR. Note the presence of nuclear AR in tumors with high CEP57 expression. Scale bar represents 100 μm. (B)
Overview of immunohistochemical staining results. No statistically significant correlation between CEP57 and AR expression was found
(P N .05; Fisher exact probability test).
494 Role of CEP57 in Prostate Cancer Mang et al. Translational Oncology Vol. 8, No. 6, 2015In more general terms, it is possible that mechanisms that promote
chromosomal instability and mechanisms that negatively affect
cellular proliferation are competing processes. With this respect,
CEP57 overexpression may have different cellular consequences when
compared with proteins such as PLK4, which is believed to have
exclusively centrosomal functions [29,30]. Biallelic mutations ofFigure 7. CEP57 is overexpressed in prostate basal cells. Immuno-
histochemical analysis of directly adjacent tissue sections from a
representative area with prostate basal cell hyperplasia (left panels)
and prostate cancer (right panels) from the same prostatectomy
specimen for CEP57, p63, FGF2, FGFR1, and Ki-67. Scale bar = 50
μm (left) or 100 μm (right).CEP57 have been detected in a subset of patients with mosaic
variegated aneuploidy syndrome [31], but how exactly loss of CEP57
leads to aneuploidy and cancer predisposition in these patients
remains to be determined. Our finding that all metastatic lesions
analyzed showed a loss of CEP57 expression together with the poor
outcome of a patient with absence of CEP57 expression in TMA II
(Figure 1), however, underscores that CEP57 loss of function can
promote malignant progression, potentially through a number of
mechanisms [17,25,26,32].
Although we could not corroborate a role of CEP57 in preventing
nuclear translocation of the AR, a crucial process targeted by several
anticancer agents in prostate cancer [15,19], this does not rule out that
other transport cargoes may be responsible for the observed effects. For
example, CEP57 has been reported to interact with cyclin D1 and to
promote cellular quiescence by preventing nuclear accumulation of
cyclin D1, thereby blocking CDK4-dependent phosphorylation of the
retinoblastoma tumor suppressor (pRB) [32]. Conversely, CEP57
overexpression caused a reduction of cells in S phase [32]. When we
performed a flow cytometric analysis of CEP57-transfected LNCaP
cells, we did not find a significant reduction of S phase cells (not shown)
pointing to cell-specific and/or dosage effects. However, we cannot rule
out that this function of CEP57 also contributes to the less aggressive
tumor growth characteristics associated with CEP57 overexpression
in vivo and/or modulates the proliferative activity of prostate basal cells.
Taken together, the findings presented here underscore an
association of high CEP57 expression with less aggressive tumor
growth. This, together with our finding that even massive microtubule
bundling induced by high CEP57 expression does not prevent AR
nuclear translocation, has important translational implications. First,
CEP57 could be used as a prognostic biomarker, ideally as part of a
panel of markers, to stratify patients into risk categories. Second, the
mode of action of microtubule-stabilizing drugs such as taxanes, which
are widely used in advanced prostate cancer, may be independent from
blocking AR trafficking. This suggests that hormonal therapy and
taxanes function, at least in part, in a nonoverlapping fashion. Although
further experiments to corroborate this are currently under way, recent
results showing an impressive overall survival benefit from adding
docetaxel to ADT in men with metastatic prostate cancer lend
important support to this notion [33].
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2015.11.004.
Figure 8. Loss of CEP57 expression in prostate cancermetastases. (A) Immunohistochemical analysis of tissue specimens frommCRPCor a
bone lesion for CEP57. Scale bar= 50 μm. (B) Overviewof staining results. Note the uniformly low expression of CEP57 inmetastatic lesions.
Figure 9. CEP57 overexpression impairs mitosis. (A) Immunofluo-
rescencemicroscopic analysis of LNCaP cells transfected (48 hours)
with empty vector (left, single cell) or CEP57 (right, doublet) using
DsRED as transfection marker (channel not shown). Note the
disarranged microtubule network in the CEP57-transfected cell and
the cytoplasmic indentations (arrows). Nuclei are stained with DAPI.
Scale bar= 10 μm. (B)Quantification of control or CEP57-transfected
cells with normal or disarrangedmicrotubule (MT) network and either
showing a single nucleus or binucleation (doublet). Each bar
represents mean and standard error of three independent experi-
ments. Asterisks indicate statistical significance (P b .05).
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